Sumanta K. Pal, MD, and Neeraj Agarwal, MD, on Prostate Cancer: The Talapro-2 Trial

2018 ASCO Annual Meeting

Sumanta K. Pal, MD, of the City of Hope, and Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discuss the ongoing phase III Talapro-2 study of talazoparib with background enzalutamide in metastatic castration-resistant prostate cancer with DNA damage–repair deficiencies (Abstract TPS5091).

Aug

Today In Oncology

FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

Issues in Doctor-Patient Discussions on Potential Harms of Lung Cancer Screening

VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer

Basal Cell Carcinoma and Risk for Development of Other Cancers

Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting

;